Oxford University-led AMALFI clinical trial results presented at the European Society of Cardiology (ESC) Congress 2025 and published in the Journal of the American Medical Association (JAMA). AMALFI ...
Please provide your email address to receive an email when new articles are posted on . Insertable cardiac monitoring was estimated to be cost-effective for AF detection in the U.S. This finding was ...
Patients with atrial fibrillation who use wearable devices, like Apple Watches and FitBits, report higher anxiety levels and increased health care usage than nonusers. Although there are concerns ...
In February 2023, NICE withdrew this guidance following a review. The original guidance published in 2013 and recommended the use of WatchBP Home A for opportunistically detecting atrial fibrillation ...
Researchers from two Lithuanian universities have developed a patient-safe monitoring technology to identify and manage individual factors provoking atrial fibrillation. The technology is a result of ...
Verily, Alphabet’s life sciences research arm, is collaborating with San Francisco-based iRhythm Technologies to develop digital health tools for screening, diagnosis and management of atrial ...
Irregular heart rhythms, such as atrial fibrillation and atrial flutter, affect millions of Americans and can increase the risk of serious complications if left untreated. Understanding the warning ...
SAN FRANCISCO, Aug. 29, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) announced results from the Oxford University-led Active Monitoring for AtriaL FIbrillation (AMALFI) randomized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results